摘要
背景:阿尔茨海默病(AD)是一种神经退行性疾病,其特征在于脑中的细胞外淀粉样蛋白斑和神经原纤维缠结(neurofibrillary tangles)。研究表明,神经元能够重新进入细胞周期,但还不足以完全复制。这导致细胞死亡和随后的神经变性。 目的:本研究旨在分析AD患者和正常人脑组织中MAPT基因和CDK5(细胞周期调控相关基因)的表达。 方法:采用实时定量PCR技术对26例AD患者和24例健康老年人脑内三个区域(内嗅皮层,听皮层和海马)的150个样本进行特征描述。 结果:当共同分析脑样品时,发现AD患者CDK5和MAPT基因表达降低。当各组样本按脑区分离并比较时,海马和内嗅皮层中CDK5的表达存在显着性差异。在这两种情况下,AD组mRNA均较低(p = 0.0001)。然而,使用MAPT基因的相同分析显示没有显着的统计学差异。当在每组中的大脑的不同区域之间比较基因表达时,没有发现统计学差异。 结论:这些结果可能有助于更好地理解CDK5和MAPT基因在AD中的参与,因为它们考虑了基于疾病进展而受到不同影响的不同大脑区域。主要挑战是在未来为这种使人衰弱的疾病建立有效的治疗方法。
关键词: 阿尔茨海默病,脑,CDK5,细胞周期,基因表达,MAPT。
Current Alzheimer Research
Title:CDK5 and MAPT Gene Expression in Alzheimer's Disease Brain Samples
Volume: 15 Issue: 2
关键词: 阿尔茨海默病,脑,CDK5,细胞周期,基因表达,MAPT。
摘要: Background: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by extracellular amyloid plaque and neurofibrillary tangles in the brain. Studies have shown that neurons are able to re-enter the cell cycle, but not enough to enable full replication. This leads to cell death and consequent neurodegeneration.
Objective: This study aimed to characterize the expression of the MAPT gene and CDK5 (the gene involved in cell cycle regulation) in brain samples from patients with AD and controls.
Method: The real-time-PCR technique was used to characterize 150 samples from three areas of the brain (entorhinal cortex, auditory cortex, and hippocampus) of 26 AD patients and 24 healthy elderly subjects.
Results: When the brain samples were analyzed collectively, a decrease in CDK5 and MAPT gene expression was found in AD patients. When each groups' samples were separated by area of the brain and compared, significant differences were found in CDK5 expression in the hippocampus and the entorhinal cortex. In both cases, mRNA was lower in the AD group (p=0.0001); however, the same analysis using the MAPT gene revealed no significant statistical differences. No statistical differences were found when gene expression was compared between the different regions of the brain within each group.
Conclusion: These results may contribute to a better understanding of the involvement of CDK5 and MAPT genes in AD in that they consider different areas of the brain that are affected differently based on disease progression. The main challenge is to establish an effective therapy for this debilitating disease in the future.
Export Options
About this article
Cite this article as:
CDK5 and MAPT Gene Expression in Alzheimer's Disease Brain Samples, Current Alzheimer Research 2018; 15 (2) . https://dx.doi.org/10.2174/1567205014666170713160407
DOI https://dx.doi.org/10.2174/1567205014666170713160407 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Click Test: A Novel Tool to Quantify the Age-Related Decline of Fast Motor Sequencing of the Thumb
Current Aging Science Update on Myositis Therapy: From Today’s Standards to Tomorrow’s Possibilities
Current Pharmaceutical Design Therapeutic Effects of Progesterone in Animal Models of Neurological Disorders
CNS & Neurological Disorders - Drug Targets Possible Protecting Role of TNF-α in Kainic Acid-induced Neurotoxicity Via Down-Regulation of NFκB Signaling Pathway
Current Alzheimer Research Conference Report: The Myriad Pathways of Neurodegeneration Discussed at NEUROCON 2015
Current Aging Science Hybrid Molecules Development: A Versatile Landscape for the Control of Antifungal Drug Resistance: A Review
Mini-Reviews in Medicinal Chemistry Towards A Multimodal Treatment of Depression: A Minireview on the Potential Role of Antibiotics
Mini-Reviews in Medicinal Chemistry Neuronal Response of Peroxisomal and Peroxisome-Related Proteins to Chronic and Acute Aβ Injury
Current Alzheimer Research Hydroximic Acid Derivatives: Pleiotropic Hsp Co-Inducers Restoring Homeostasis and Robustness
Current Pharmaceutical Design Phytochemistry and Pharmacological Update on Tetraterpenoids
The Natural Products Journal Discovery of Novel Compounds Targeting DJ-1 as Neuroprotectants for Parkinson’s Disease by Virtual Screening and In Silico Method
Current Computer-Aided Drug Design Aberrant Neuronal Activity and Dysfunctional Connectivity in Aβ<sub>1–42</sub>- mediated Memory Deficits in Rats
Current Alzheimer Research The Proinflammatory Cytokine GITRL Contributes to TRAIL-mediated Neurotoxicity in the HCN-2 Human Neuronal Cell Line
Current Alzheimer Research The Contribution of Cerebral Vascular Neuropathology to Mild Stage of Alzheimer’s Dementia Using the NACC Database
Current Alzheimer Research Novel AβIsoforms in Alzheimer's Disease - Their Role in Diagnosis and Treatment
Current Pharmaceutical Design Possible Therapeutic Targets in Cardiac Myocyte Apoptosis
Current Pharmaceutical Design Proteasomes as Drug Targets
Current Drug Targets A Study on Identification of Nutraceutical Value of New Imidazolone Schiff Base Analogues
Letters in Drug Design & Discovery Medicinal Plants in Neurodegenerative Diseases: Perspective of Traditional Persian Medicine
Current Drug Metabolism Relationship Between the Chemokine Receptor CCR5 and Microglia in Neurological Disorders: Consequences of Targeting CCR5 on Neuroinflammation, Neuronal Death and Regeneration in a Model of Epilepsy
CNS & Neurological Disorders - Drug Targets